Is Evoke Pharma Stock a Good Investment?
Evoke Pharma Investment Advice | EVOK |
- Examine Evoke Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evoke Pharma's leadership team and their track record. Good management can help Evoke Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Evoke Pharma's business and its evolving consumer preferences.
- Compare Evoke Pharma's performance and market position to its competitors. Analyze how Evoke Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Evoke Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evoke Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evoke Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evoke Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Evoke Pharma Stock
Researching Evoke Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evoke Pharma recorded a loss per share of 10.13. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 1st of August 2024.
To determine if Evoke Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evoke Pharma's research are outlined below:
| Evoke Pharma had very high historical volatility over the last 90 days | |
| Evoke Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02. | |
| Latest headline from MacroaxisInsider: Insider Trading |
Evoke Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evoke Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evoke Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Evoke Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Evoke Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.21 | -0.17 | 0.04 | 19 | ||
2024-03-14 | 2023-12-31 | -0.5 | -0.59 | -0.09 | 18 | ||
2023-05-15 | 2023-03-31 | -0.58 | -0.67 | -0.09 | 15 | ||
2023-11-09 | 2023-09-30 | -0.62 | -0.51 | 0.11 | 17 | ||
2022-08-10 | 2022-06-30 | -0.6 | -0.71 | -0.11 | 18 | ||
2021-11-10 | 2021-09-30 | -0.84 | -0.72 | 0.12 | 14 | ||
2021-08-12 | 2021-06-30 | -0.96 | -0.84 | 0.12 | 12 | ||
2018-11-13 | 2018-09-30 | -0.96 | -1.08 | -0.12 | 12 |
Know Evoke Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Evoke Pharma's institutional investor refers to the entity that pools money to purchase Evoke Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 70.5 K | Bleichroeder Lp | 2024-09-30 | 68.8 K | Nantahala Capital Management, Llc | 2024-09-30 | 56.2 K | Corsair Capital Management Llc | 2024-09-30 | 11.7 K | Tower Research Capital Llc | 2024-09-30 | 816 | Ubs Group Ag | 2024-09-30 | 90.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 31.0 | Bank Of America Corp | 2024-09-30 | 25.0 |
Evoke Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.35 M.Market Cap |
|
Evoke Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
Determining Evoke Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Evoke Pharma is a good buy. For example, gross profit margin measures Evoke Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evoke Pharma's profitability and make more informed investment decisions.
Evaluate Evoke Pharma's management efficiency
Evoke Pharma has return on total asset (ROA) of (0.335) % which means that it has lost $0.335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4991) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (9.26) | (9.72) | |
| Tangible Book Value Per Share | (9.26) | (9.72) | |
| Enterprise Value Over EBITDA | (0.52) | (0.54) | |
| Price Book Value Ratio | (1.36) | (1.29) | |
| Enterprise Value Multiple | (0.52) | (0.54) | |
| Price Fair Value | (1.36) | (1.29) | |
| Enterprise Value | 3.8 M | 3.6 M |
The management team at Evoke Pharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 0.348 |
Basic technical analysis of Evoke Stock
As of the 11th of December 2024, Evoke Pharma shows the Mean Deviation of 3.81, coefficient of variation of 3790.76, and Downside Deviation of 5.0. Evoke Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Evoke Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evoke Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evoke Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evoke Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nantahala Capital Management, Llc a day ago Insider Trading | ||
Nantahala Capital Management, Llc 2 days ago Insider Trading | ||
Nantahala Capital Management, Llc 3 days ago Insider Trading | ||
Nantahala Capital Management, Llc few days ago Insider Trading | ||
Nantahala Capital Management, Llc few days ago Insider Trading | ||
Reed Vickie S six days ago Acquisition by Reed Vickie S of 58000 shares of Evoke Pharma subject to Rule 16b-3 | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Brady Todd C over a week ago Acquisition by Brady Todd C of 57750 shares of Evoke Pharma at 1.55 subject to Rule 16b-3 | ||
Nantahala Capital Management, Llc over a week ago Insider Trading |
Evoke Pharma's Outstanding Corporate Bonds
Evoke Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evoke Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evoke bonds can be classified according to their maturity, which is the date when Evoke Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| EVERSOURCE ENERGY 33 Corp BondUS30040WAE84 | View | |
| EVERSOURCE ENERGY 425 Corp BondUS30040WAF59 | View | |
| EVERSOURCE ENERGY 335 Corp BondUS30040WAB46 | View | |
| ES 14 15 AUG 26 Corp BondUS30040WAN83 | View | |
| ES 255 15 MAR 31 Corp BondUS30040WAL28 | View | |
| US30040WAK45 Corp BondUS30040WAK45 | View | |
| US30040WAJ71 Corp BondUS30040WAJ71 | View |
Understand Evoke Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Evoke Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0279 | |||
| Market Risk Adjusted Performance | 0.1477 | |||
| Mean Deviation | 3.81 | |||
| Semi Deviation | 4.76 | |||
| Downside Deviation | 5.0 | |||
| Coefficient Of Variation | 3790.76 | |||
| Standard Deviation | 6.18 | |||
| Variance | 38.22 | |||
| Information Ratio | 0.0063 | |||
| Jensen Alpha | 0.0259 | |||
| Total Risk Alpha | (0.83) | |||
| Sortino Ratio | 0.0077 | |||
| Treynor Ratio | 0.1377 | |||
| Maximum Drawdown | 48.38 | |||
| Value At Risk | (7.18) | |||
| Potential Upside | 5.83 | |||
| Downside Variance | 24.99 | |||
| Semi Variance | 22.61 | |||
| Expected Short fall | (4.22) | |||
| Skewness | 2.39 | |||
| Kurtosis | 13.17 |
| Risk Adjusted Performance | 0.0279 | |||
| Market Risk Adjusted Performance | 0.1477 | |||
| Mean Deviation | 3.81 | |||
| Semi Deviation | 4.76 | |||
| Downside Deviation | 5.0 | |||
| Coefficient Of Variation | 3790.76 | |||
| Standard Deviation | 6.18 | |||
| Variance | 38.22 | |||
| Information Ratio | 0.0063 | |||
| Jensen Alpha | 0.0259 | |||
| Total Risk Alpha | (0.83) | |||
| Sortino Ratio | 0.0077 | |||
| Treynor Ratio | 0.1377 | |||
| Maximum Drawdown | 48.38 | |||
| Value At Risk | (7.18) | |||
| Potential Upside | 5.83 | |||
| Downside Variance | 24.99 | |||
| Semi Variance | 22.61 | |||
| Expected Short fall | (4.22) | |||
| Skewness | 2.39 | |||
| Kurtosis | 13.17 |
Consider Evoke Pharma's intraday indicators
Evoke Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evoke Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 331.04 | |||
| Daily Balance Of Power | (1.12) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 4.17 | |||
| Day Typical Price | 4.14 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.19) |
Evoke Pharma Corporate Filings
| 22nd of November 2024 Other Reports | ViewVerify | |
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Evoke Stock media impact
Far too much social signal, news, headlines, and media speculation about Evoke Pharma that are available to investors today. That information is available publicly through Evoke media outlets and privately through word of mouth or via Evoke internal channels. However, regardless of the origin, that massive amount of Evoke data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evoke Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evoke Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evoke Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evoke Pharma alpha.
Evoke Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Evoke Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evoke Pharma Corporate Management
| Mark CPA | Chief Officer | Profile | |
| DMD MD | Chief Officer | Profile | |
| Christopher Quesenberry | Chief Gimoti | Profile | |
| Marilyn Carlson | Chief Medical Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Evoke Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.